New to site?


Login

Lost password? (X)

Already have an account?


Signup

(X)
Farooq

AstraZeneca divests rights for Losec to Cheplapharm

HomeINDUSTRY NEWSAstraZeneca divests rights for Losec to Cheplapharm
01
Oct
AstraZeneca divests rights for Losec to Cheplapharm

AstraZenecaAstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm). The divestment includes medicines containing omeprazole marketed by AstraZeneca or its collaborators under the Acimax, Antra, Mepral, Mopral, Omepral and Zoltum medicine names.Original Article

Tags:

    Related Posts
    Leave A Comment

    Leave A Comment